Sensitive and specific assessment of recombinant von Willebrand factor in platelet function analyzer

References

• Kragh T, Napoleone M, Fallah MA, Gritsch H, Schneider MF, Reininger AJ. High shear dependent vonwillebrand factor self-assembly fostered by platelet interaction and controlled by ADAMTS13. Thromb Res. 2014;133:1079–1087.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Clinical utility of closure times using the platelet function analyzer-100/200. Am J Hematol. 2017;92:398–404.
   PubMed Web of Science ®Google Scholar
• Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neumann C, Trossaert M; et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood. 1998;91:1325–1331.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost. 2008;34:709–733.
   PubMed Web of Science ®Google Scholar
• Bodo I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J; et al. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13:1345–1350.
   PubMed Web of Science ®Google Scholar
• Just S. Laboratory testing for von willebrand disease: the past, present, and future state of play for von willebrand factor assays that measure platelet binding activity, with or without ristocetin. Semin Thromb Hemost. 2017;43:75–91.
   PubMed Web of Science ®Google Scholar
• Patzke J, Budde U, Huber A, Mendez A, Muth H, Obser T; et al. Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin. Blood Coagul Fibrinolysis. 2014;25:860–870.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Bonar R. External quality assessment/proficiency testing and internal quality control for the PFA-100 and PFA-200: an update. Semin Thromb Hemost. 2014;40:239–253.
   PubMed Web of Science ®Google Scholar
• Turecek PL, Schrenk G, Rottensteiner H, Varadi K, Bevers E, Lenting P; et al. Structure and function of a recombinant von Willebrand factor drug candidate. Semin Thromb Hemost. 2010;36:510–521.
   PubMed Web of Science ®Google Scholar
• Turecek PL, Mitterer A, Matthiessen HP, Gritsch H, Varadi K, Siekmann J; et al. Development of a plasma- and albumin-free recombinant von Willebrand factor. Hamostaseologie. 2009;29(Suppl 1):S32–8.
   PubMed Web of Science ®Google Scholar
• Ott HW, Griesmacher A, Schnapka-Koepf M, Golderer G, Sieberer A, Spannagl M; et al. Analysis of von Willebrand factor multimers by simultaneous high- and low-resolution vertical SDS-agarose gel electrophoresis and Cy5-labeled antibody high-sensitivity fluorescence detection. Am J Clin Pathol. 2010;133:322–330.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Pasalic L, Curnow J. Monitoring Therapy during Treatment of von Willebrand Disease. Semin Thromb Hemost. 2017;43:338–354.
   PubMed Web of Science ®Google Scholar
• Laffan MA, Lester W, O’Donnell JS, Will A, Tait RC, Goodeve A; et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014;167:453–465.
   PubMed Web of Science ®Google Scholar
• Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia. 2004;10:243–249.
   PubMed Web of Science ®Google Scholar
• Budde U, Metzner HJ, Muller HG. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Hemost. 2006;32:626–635.
   PubMed Web of Science ®Google Scholar
• Batlle J, Lopez-Fernandez MF, Fraga EL, Trillo AR, Perez-Rodriguez MA. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Blood Coagul Fibrinolysis. 2009;20:89–100.
   PubMed Web of Science ®Google Scholar
• Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J; et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood. 2004;103:2032–2038.
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood. 1997;90:2515–2521.
   PubMed Web of Science ®Google Scholar
• Fressinaud E, Veyradier A, Sigaud M, Boyer-Neumann C, Le Boterff C, Meyer D. Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates. Br J Haematol. 1999;106:777–783.
   PubMed Web of Science ®Google Scholar
• Michiels JJ, Smejkal P, Penka M, Batorova A, Pricangova T, Budde U; et al. Diagnostic differentiation of von willebrand disease types 1 and 2 by von willebrand factor multimer analysis and DDAVP Challenge Test. Clin Appl Thromb Hemost. 2017;Sep;23(6):518–531. doi: 10.1177/1076029616647157. Epub 2016 Jul 21.
   PubMed Web of Science ®Google Scholar
• Van Vliet HH, Kappers-Klunne MC, Leebeek FW, Jj M. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2. Thromb Haemost. 2008;100:462–468.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Kempton C, Millar C, Romond E, Shapiro A, Birschmann I; et al. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood. 2013;122:648–657.
   PubMed Web of Science ®Google Scholar
• Gill JC, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek FW; et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126:2038–2046.
   PubMed Web of Science ®Google Scholar
• Van Belle E, Rauch A, Vincent F, Robin E, Kibler M, Labreuche J; et al. Von willebrand factor multimers during transcatheter aortic-valve replacement. N Engl J Med. 2016;375:335–344.
   PubMed Web of Science ®Google Scholar
• Van Belle E, Rauch A, Vincentelli A, Jeanpierre E, Legendre P, Juthier F; et al. Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions. Circ Res. 2015;116:1193–1201.
   PubMed Web of Science ®Google Scholar
• Vincentelli A, Susen S, LeTourneau T, Six I, Fabre O, Juthier F; et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349:343–349.
   PubMed Web of Science ®Google Scholar
• Gill JC, Wilson AD, Endres-Brooks J, Montgomery RR. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood. 1986;67:758–761.
   PubMed Web of Science ®Google Scholar
• Federici AB, Budde U, Castaman G, Rand JH, Tiede A. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost. 2013;39:191–201.
   PubMed Web of Science ®Google Scholar
• Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science. 2009;324:1330–1334.
   PubMed Web of Science ®Google Scholar
• Pareti FI, Lattuada A, Bressi C, Zanobini M, Sala A, Steffan A; et al. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation. 2000;102:1290–1295.
   PubMed Web of Science ®Google Scholar
• Lippok S, Radtke M, Obser T, Kleemeier L, Schneppenheim R, Budde U; et al. Shear-Induced Unfolding and Enzymatic Cleavage of Full-Length VWF Multimers. Biophys J. 2016;110:545–554.
   PubMed Web of Science ®Google Scholar
• Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL; et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14:171–232.
   PubMed Web of Science ®Google Scholar